拱東醫療(605369.SH):控股子公司鄭州拱東註冊成立
格隆匯5月13日丨拱東醫療(605369.SH)公佈,近日,鄭州拱東取得了鄭州航空港經濟綜合試驗區市場監督管理局頒發的《營業執照》,鄭州拱東註冊資本為人民幣6,000萬元,其中公司認繳出資額人民幣4,200萬元,佔註冊資本的70%;安圖生物認繳出資額人民幣1,800萬元,佔註冊資本的30%。股東安圖生物系公司重要客户。
本次公司投資設立的鄭州拱東,將專注於醫用高分子耗材及相關產品、服務的研發、生產與銷售,與公司的業務及戰略規劃相匹配;有利於藉助合資方及其團隊在行業和區域市場的豐富經驗和市場基礎,延伸公司產業鏈及加強公司在中原地區的市場拓展,進一步完善公司業務佈局,提升公司綜合競爭力;進一步優化公司業務結構和資產結構,促進公司持續高質量穩健發展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.